Biomarkers: Respiratory infections, ards, clinical advances.

Jürgen Becker*

Department of Respiratory Medicine, Charité – Universitätsmedizin Berlin, Germany

Introduction

Host-derived biomarkers are proving valuable in the diagnostic and prognostic management of lung infections. A systematic review underscores their potential to significantly improve patient care, though it critically highlights the essential requirement for more rigorous clinical trials to thoroughly validate their real-world effectiveness and widespread applicability [1].

For ventilator-associated pneumonia, soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) has emerged as a promising diagnostic biomarker. A meta-analysis examining its accuracy indicates its potential clinical utility, but emphasizes that further validation through well-designed, comprehensive clinical studies is indispensable to confirm its reliability and integration into practice [2].

New and emerging biomarkers for Acute Respiratory Distress Syndrome (ARDS) in patients suffering from sepsis are currently under close examination. This review elaborates on how these novel markers could facilitate earlier detection, enable more precise prognostication, and support the development of highly personalized treatment strategies, thereby stressing the ongoing need for dedicated clinical research in this critical area [3].

The diagnostic landscape for bacterial lung infections is expanding to include non-invasive techniques. A systematic review specifically explores the potential of volatile organic compounds (VOCs) found in exhaled breath as non-invasive biomarkers. It details the current progress within this innovative field and thoughtfully outlines the significant challenges that must be systematically addressed before widespread clinical application can be realized [4].

In the management of lower respiratory tract infections, procalcitonin-guided antibiotic stewardship has demonstrated clear benefits. A meta-analysis of randomized controlled trials confirms its effectiveness in substantially reducing antibiotic exposure while concurrently improving patient clinical outcomes, offering valuable, evidence-based insights that significantly inform current clinical practice [5].

Biomarkers for bacterial community-acquired pneumonia are a crucial area of study. A comprehensive review provides a current overview of these markers, meticulously delving into their diagnostic and prognostic capabilities. It highlights both the notable achievements made in integrating these markers and the persistent, complex challenges that remain in their routine clinical application [6].

For sepsis-induced Acute Respiratory Distress Syndrome, the utility of various serum biomarkers in both diagnosis and outcome prediction is being actively investigated. This article suggests that these markers hold considerable promise for guiding informed clinical decisions and precisely tailoring therapeutic strategies for affected patients, potentially enhancing their care [7].

Pediatric respiratory infections also benefit from biomarker research. A systematic review specifically examines host biomarkers for diagnosing and prognosticating viral lower respiratory tract infections in children. It identifies several promising candidates and importantly underscores the critical need for further rigorous validation through robust clinical trials to firmly establish their practical utility in this vulnerable population [8].

In the demanding environment of intensive care, the identification of early diagnostic and prognostic biomarkers for pneumonia in critically ill patients is paramount. A dedicated review highlights the profound significance of these markers in guiding timely and effective interventions, which are essential for ultimately improving patient outcomes within challenging intensive care environments [9].

The future of Acute Respiratory Distress Syndrome (ARDS) management lies in precision medicine. An insightful article discusses the current status and future directions of this approach, focusing on how biomarkers and genetic factors can stratify patients and guide individualized therapies. It strongly emphasizes the pivotal role of ongoing and future clinical trials in driving this significant advancement [10].

***Correspondence to:** Jürgen Becker, Department of Respiratory Medicine, Charité – Universitätsmedizin Berlin, Germany. E-mail: juergen.becker@charite.de

Received: 01-Jul-2025, Manuscript No. AAJPCR-25-213; **Editor assigned:** 03-Jul-2025, Pre QC No. AAJPCR-25-213 *(PQ)*; **Reviewed:** 23-Jul-2025, QC No. AAJPCR-25-213; **Revised:** 01-Aug-2025, Manuscript No. AAJPCR-25-213 *(R)*; **Published:** 12-Aug-2025, DOI: 10.35841/aajpcr-8.4.213

Citation: Becker J. Biomarkers: Respiratory infections, ards, clinical advances. J Pulmonol Clin Res. 2025;08(04):213.

Conclusion

This collection of research highlights significant advancements and ongoing challenges in the field of biomarkers for respiratory infections and acute respiratory distress syndrome (ARDS). Several systematic reviews and meta-analyses explore the potential of host-derived biomarkers for diagnosing lung infections, predicting patient outcomes, and identifying specific conditions like ventilator-associated pneumonia and viral lower respiratory tract infections in children. These studies consistently emphasize the need for rigorous clinical validation to translate promising findings into routine clinical practice.

Novel approaches include the investigation of volatile organic compounds in exhaled breath as non-invasive diagnostic tools for bacterial lung infections. The utility of procalcitonin-guided antibiotic stewardship for lower respiratory tract infections is also well-supported, demonstrating its role in reducing antibiotic exposure and improving outcomes. Research further delves into biomarkers for bacterial community-acquired pneumonia, sepsis-induced ARDS, and early diagnosis of pneumonia in critically ill patients, all aiming to guide timely interventions and personalized therapies. The broader application of precision medicine in ARDS, leveraging biomarkers and genetic factors, underscores the future direction of individualized patient management, with clinical trials remaining central to these advancements. This body of work collectively shows a strong focus on improving diagnostic accuracy, prognostic capabilities, and therapeutic strategies through biomarker-driven approaches.

References

1. Gemma P, Elena P, David M. Host-derived biomarkers for diagnosis and prognosis of lung infections: a systematic review. *Rev Esp Quimioter.* 2020;33:180-192.
2. Ning Z, Huili C, Bing Y. Accuracy of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in diagnosis of ventilator-associated pneumonia: A meta-analysis. *Medicine* (Baltimore). 2020;99:e19904.
3. Ying Z, Xiaofei Z, *Yanhong H. Novel Biomarkers for Acute Respiratory Distress Syndrome in Patients with Sepsis. Med Sci Monit.* 2019;25:2992-3001.
4. Sofie V, Anouk B, Lieske B. Exhaled Breath Volatile Organic Compounds for the Diagnosis of Bacterial Lung Infections: *A Systematic Review. J Clin Med.* 2022;11:4292.
5. Yu H, Huili C, Bing Y. Procalcitonin-guided antibiotic stewardship for lower respiratory tract infections: A systematic review and meta-analysis of randomized controlled trials. *Clin Respir J.* 2020;14:3-15.
6. Lionel S, Charles-Edouard L, Jean C. Biomarkers for bacterial community-acquired pneumonia: state of the art, challenges and future perspectives. *Eur Respir J.* 2019;54:1900192.
7. Bing F, Xue L, Min Z. The utility of serum biomarkers for the diagnosis and prognosis of sepsis-induced acute respiratory distress syndrome. *Crit Care.* 2021;25:103.
8. Markus T, Nicole R, Yvette D. Host biomarkers for diagnosis and prognosis of viral lower respiratory tract infections in children: a systematic review. *Clin Infect Dis.* 2020;70:915-927.
9. Shuang L, Yue W, *Chuan X. Early Diagnostic and Prognostic Biomarkers for Pneumonia in Critically Ill Patients. Mediators Inflamm.* 2021;2021:6654160.
10. Chao F, Zheng Z, Jie P. Advances in precision medicine for acute respiratory distress syndrome: current status and future perspectives. *Signal Transduct Target Ther.* 2021;6:111.

Citation: *Becker J. Biomarkers: Respiratory infections, ards, clinical advances. J Pulmonol Clin Res. 2025;08(04):213.*